GLP-1 Receptor Agonists Don't Raise Thyroid Cancer Risk
A cohort study in three Scandinavian countries found no significant increase in thyroid cancer risk with glucagon-like peptide 1 receptor agonists.
Stay updated with breaking news from Thyroid Carcinoma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A cohort study in three Scandinavian countries found no significant increase in thyroid cancer risk with glucagon-like peptide 1 receptor agonists.
In this large population based cohort study, Qianwei Liu and co-workers explore how a diagnosis of cancer in children influences suicide risk in parents.
Of all new, dedicated thyroid ultrasounds performed at a single tertiary care center, only a quarter identified biopsy-recommended nodules, whereas nearly 40% did not find any nodules.
Doctors who prescribe this class of medication should be aware of the rare side effects with which it is associated, said an obesity expert.
A small study suggests that environmental PFAS exposure may raise the risk for thyroid cancer. But a biostatistician who reviewed the findings is not convinced.